April 22, 2018 10:33 PM ET

Healthcare Equipment and Supplies

Company Overview of Nevro Corp.

Company Overview

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

1800 Bridge Parkway

Redwood City, CA 94065

United States

Founded in 2006

676 Employees

Phone:

650-251-0005

Key Executives for Nevro Corp.

President, CEO & Director
Age: 38
Total Annual Compensation: $462.2K
Chief Financial Officer
Age: 61
Total Annual Compensation: $331.0K
Vice President of Operations
Age: 57
Total Annual Compensation: $241.5K
Vice President of Quality
Age: 56
Total Annual Compensation: $305.0K
Vice President of Research & Development
Age: 47
Total Annual Compensation: $274.2K
Compensation as of Fiscal Year 2016.

Nevro Corp. Key Developments

Nevro Corp. Announces Availability of MRI Conditional Labeling for the Senza Spinal Cord Stimulation System Delivering HF10 Therapy in United States

Nevro Corp. announced that full-body magnetic resonance imaging (MRI) conditional labeling is now available in the United States for the Senza Spinal Cord Stimulation (SCS) System delivering HF10 therapy. This labeling expansion, which is now applicable in all the markets, adds to the previous labeling allowing head and extremity MRI scans, broadening the pool of patients who are eligible to receive the Senza SCS System. This approval is retroactive, meaning that the new labeling for expanded imaging applies to all patients currently implanted with the Senza SCS System and percutaneous leads. It is anticipated that a similar labeling expansion will follow for the Senza II SCS system. The Senza and Senza II systems are the only SCS systems that deliver Nevro's proprietary HF10® therapy, an SCS therapy that provides electrical pulses to the spinal cord to alleviate pain. The electrical pulses are delivered by small electrodes on leads that are placed near the spinal cord and are connected to a compact, battery-powered generator implanted under the skin. HF10 therapy is the only SCS therapy indicated to provide pain relief without paresthesia (a stimulation-induced sensation, such as tingling or buzzing, which is the basis of traditional SCS) and is also the first SCS therapy to demonstrate superiority to traditional SCS for back and leg pain in a comparative pivotal study. Nevro's innovations in SCS, including the Senza System and Senza II System and HF10 Therapy, are covered by more than 150 issued U.S. and international patents.

Nevro Corp. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Months Ended December 31, 2017; Reiterates Revenue Guidance for the Full Year of 2018

Nevro Corp. reported unaudited consolidated earnings results for the fourth quarter and full year months ended December 31, 2017. For the quarter, the company reported, revenue of $97,963,000, loss from operations of $2,172,000, loss before income taxes of $3,919,000, net loss of $4,311,000, compared to revenue of $70,531,000, loss from operations of $6,269,000, loss before income taxes of $9,242,000, net loss of $9,825,000, for the same period a year ago. Net loss per share, basic and diluted was $0.15 against $0.34 a year ago. For the year to date, the company reported, revenue of $326,674,000, loss from operations of $29,579,000, loss before income taxes of $35,250,000, net loss of $36,658,000, compared to revenue of $228,504,000, loss from operations of $23,081,000, loss before income taxes of $30,155,000, net loss of $31,778,000, for the same period a year ago. Net loss per share, basic and diluted was $1.25 against $1.12 a year ago. For the full year of 2018, the company reiterates worldwide to be in the range of $400.0 to $410.0 million, which was first announced in January 2018. The company expected gross margin of 70% to 71% range.

Nevro Corp. to Report Q4, 2017 Results on Feb 22, 2018

Nevro Corp. announced that they will report Q4, 2017 results at 5:00 PM, Eastern Standard Time on Feb 22, 2018

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
206 Ortho, Inc. United States
21st Century Scientific, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nevro Corp., please visit www.nevro.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.